Company News

Share this article:
Novartis announced an agreement with Vanda Pharmaceuticals for exclusive US and Canandian rights for Fanapt, a schizophrenia treatment approved by FDA in May. The agreement included an upfront payment of $200 million, and potential milestones and sales royalties in the future. Vanda retained rights to the drug outside of the US and Canada, although Novartis has the option to discuss further collaboration as new opportunities arise.

Onyx Pharmaceuticals will acquire Proteolix, Inc., a privately-held biopharmaceutical company focused on discovering and developing therapies for hematological malignancies and solid tumors. Onyx will pay $276 million for the company, and other milestone payments pending regulatory approvals. Proteolix's lead compound is currently in clinical trials, including a phase 2b trial for relapsed and refractory multiple myeloma.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.